bioMérieux to acquire the remaining 80% stake in SpinChip for €111m.

bioMérieux, a diagnostic systems, reagents, software and services provider, agreed to acquire the remaining 80% stake in SpinChip, a medical device company developing immunoassay diagnostics platform, for €111m. “The dedication of the SpinChip team over the past decade has been exceptional. Their relentless efforts have led to the development of a groundbreaking diagnostics platform that has the potential to significantly improve healthcare outcomes for patients. Our recent collaboration with bioMérieux has been highly productive and has brought us closer to the commercialisation of the platform. I am confident that bioMérieux’s leadership will effectively utilise the platform’s potential to provide efficient and improved diagnostic solutions for patients and healthcare workers worldwide,” Morten Jurs, SpinChip CEO.